No abstract available.
Endometrial Neoplasms ; Female

No abstract available.
Female ; Fertility Preservation/*methods ; Humans ; Ovarian Neoplasms/*surgery

No abstract available.
Colorectal Neoplasms, Hereditary Nonpolyposis*

Endometrial cancer is the most common gynecologic malignancy in the developed countries. Although the high incidence of this occurrence no consensus, about the role of retroperitoneal staging, still exists. Growing evidence support the safety and efficacy of sentinel lymph node mapping. This technique is emerging as a new standard for endometrial cancer staging procedures. In the present paper, we discuss the role of sentinel lymph node mapping in endometrial cancer, highlighting the most controversies features.
Endometrial Neoplasms/*pathology/surgery ; Female ; Humans ; Hysteroscopy/methods ; Injections, Intralesional ; Lymph Node Excision/*methods ; Lymphatic Metastasis ; *Sentinel Lymph Node Biopsy/methods

No abstract available.
Female ; Humans ; Leiomyoma/*surgery ; *Morcellation/adverse effects ; Risk Assessment ; United States ; United States Food and Drug Administration ; Uterine Neoplasms/*surgery

No abstract available.
Female ; Humans ; Leiomyoma/*surgery ; *Morcellation/adverse effects ; Risk Assessment ; United States ; United States Food and Drug Administration ; Uterine Neoplasms/*surgery

No abstract available.
Endometrial Neoplasms/*pathology ; Female ; Humans ; Lymph Node Excision/*methods ; *Sentinel Lymph Node Biopsy

Endometrial cancer (EC) represents the most common gynecological neoplasm in developed countries. Surgery is the mainstay of treatment for EC. Although EC is characterized by a high prevalence several features regarding its management are still unclear. In particular the execution of lymphadenectomy is controversial. The recent introduction of sentinel node mapping represents the mid-way between the execution and omission of node dissection in EC patients. In the present review we discuss the emerging role of sentinel node mapping in EC. In addition, we discussed how type of tracers utilized and site of injection impacted on sentinel node detection rates. Future perspective regarding EC management are also discussed.
Developed Countries ; Endometrial Neoplasms* ; Female ; Humans ; Laparoscopy ; Lymph Node Excision ; Prevalence ; Robotic Surgical Procedures

OBJECTIVE: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). METHODS: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. RESULTS: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) >1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16–6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29–7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29–1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12–7.74; p=0.027) were independently associated with an improved overall survival. CONCLUSION: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.
Comorbidity ; Cytoreduction Surgical Procedures ; Disease-Free Survival ; Drug Therapy ; Female ; Follow-Up Studies ; Gynecologic Surgical Procedures ; Humans ; Multivariate Analysis ; Neoplasm Metastasis ; Obstetrics ; Ovarian Neoplasms* ; Proportional Hazards Models ; Prospective Studies ; Recurrence ; Retrospective Studies ; Survivors

The World Health Organization (WHO) classified the novel coronavirus (i.e., coronavirus disease 2019 [COVID-19]) as a global public health emergency. COVID-19 threatens to curtail patient access to evidence-based treatment. Medicine is changing, basically due to the limited available resources. In the field of gynecologic oncology, we have to re-design our treatments' paradigm. During COVID-19 pandemic outbreak, the highest priority is to achieve the maximum benefit from less demanding procedures. Extensive procedures should be avoided, in order to reduce hospitalization and postoperative events that might increase the in-hospital spread of the virus. There are ongoing concerns on the use of laparoscopic procedures, related to the possible contamination of the staff working in the operation room.Other minimally invasive techniques, including, vaginal surgery as well as robotic-assisted and isobaric procedures would be preferred over laparoscopy. A fair allocation of resources is paramount adequate treatments.